You just read:

Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program

News provided by

Janssen Research & Development, LLC

Oct 02, 2017, 08:00 ET